Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy

Drug News and Perspectives

Volumn 16, Issue 6, 2003, Pages 363-369

  Sajadi, Saeid ^a   Ezekowitz, Michael D ^a   Dhond, Abhay ^a   Netrebko, Pavlo ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE INACTIVATED BLOOD CLOTTING FACTOR 7A; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; BLOOD CLOTTING INHIBITOR; MONOCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; ENDOTHELIUM INJURY; HEMOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; RESTENOSIS; REVIEW; THROMBOGENESIS;

ANIMALS; ARTERIOSCLEROSIS; FACTOR VIIA; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; RECOMBINANT PROTEINS; THROMBOPLASTIN;

EID: 0141535106     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.6.829308     Document Type: Review

References (74)

1. Camera, M., Giesen, P.L.A., Fallon, J. et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999, 19: 531.
2. Schecter, A.D., Giesen, P.L., Taby, O. et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997, 100: 2276-85.
3. Thiruvikraman, S.V., Guha, A., Roboz, J., Taubman, M.B., Nemerson, Y. and Fallon, J.T. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996, 75: 451-61.
4. Corseaux, D., Meurice, T., Six, I. et al. Basic fibroblast growth factor increases tissue factor expression in circulating monocytes and in vascular wall. Circulation 2000, 101: 2000-6.
5. Corseaux, D., Le Tourneau, T., Six, I. et al. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: Inhibition with dietary L-arginine. Circulation 1998, 98: 1776-82.
6. Doshi, S.N. and Marmur, J.D. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002, 30 (Suppl.): 241-50.
7. Le, D.T., Rapaport, S.I. and Rao, L.V. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992, 267: 15447-54.
8. Greeno, E.W., Bach, R.R. and Moldow, C.F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996, 75: 281-9.
9. Wolberg, A.S., Monroe, D.M., Roberts, H.R. et al. Tissue factor de-encryption: Ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999, 10: 201-10.
10. Wolberg, A.S., Kon, R.H., Monroe, D.M. et al. Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun 2000, 272: 332-6.
11. Giesen, P.L., Rauch, U., Bohrmann, B. et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999, 96: 2311-5.
12. Rauch, U. and Nemerson, Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000, 10: 139-43.
13. Armstrong, M.J., Storch, J. and Dainiak, N. Structurally distinct plasma membrane regions give rise to extracellular membrane vesicles in normal and transformed lymphocytes. Biochim Biophys Acta 1988, 946: 106-12.
14. Falk, E., Shah, P.K. and Fuster, V. Coronary plaque disruption. Circulation 1995, 92: 657-71.
15. Gutstein, D.E. and Fuster, V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 1999, 41: 323-33.
16. Nemerson, Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992, 29: 170-6.
17. Camerer, E., Gjernes, E., Wiiger, M. et al. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000, 275: 6580-5.
18. Muller, W.A. and Weigl, S.A. Monocyte-selective transendothelial migration: Dissection of the binding and transmigration phases by an in vitro assay. J Exp Med 1992, 176: 819-28.
19. Zhang, Y., Deng, Y., Luther, T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994, 94: 1320-7.
20. Broze, G.J. Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992, 29: 159-69.
21. Huang, Z.F., Wun, T.C. and Broze, G.J. Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993, 268: 26950-5.
22. Bajaj, M.S., Kuppuswamy, M.N., Saito, H. et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990, 87: 8869-73.
23. Osterud, B., Bajaj, M.S. and Bajaj, S.P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions: On behalf of the Subcommittee on Tissue factor Path-way Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995, 73: 873-5.
24. Novotny, W.F., Girard, T.J., Miletich, J.P. et al. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988, 72: 2020-5.
25. Lupu, C., Goodwin, C.A., Westmuckett, A.D. et al. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae: Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997, 17: 2964-74.
26. Kokawa, T., Abumiya, T., Kimura, T. et al. Tissue factor pathway inhibitor activity in human plasma: Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995, 15: 504-10.
27. Abildgaard, U. Tissue factor pathway inhibitor and heparin. Adv Exp Med Biol 1992, 313: 199-204.
28. Virmani, R., Burke, A.P. and Farb, A. Sudden cardia death. Cardiovasc Pathol 2001, 10: 211-8.
29. Annex, B.H., Denning, S.M., Channon, K.M. et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circualtion 1995, 91: 619-22.
30. Moreno, P.R., Bernardi, V.H., López Cuellar, J. et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina - Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996, 94: 3090-7.
31. Ardissino, D., Merlini, P.A., Ariens, R., Coppola, R., Bramucci, E. and Marmucci, P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997, 349: 769-71.
32. Suefuji, H., Ogawa, H., Yasue, H. et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997, 134 (Part 1): 253-9.
33. Soejima, H., Ogawa, H., Yasue, H. et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999, 99: 2908-13.
34. Toschi, V., Gallo, R., Lettino, M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997, 95: 594-9.
35. Misumi, K., Ogawa, H., Yasue, H. et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998, 81: 22-6.
36. Falciani, M., Gori, A.M., Fedi, S. et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998, 79: 495-9.
37. Kamikura, Y., Wada, H., Yamada, A. et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997, 55: 183-7.
38. Sandset, P.M., Sirnes, P.A. and Abildgaard, U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989, 72: 391-6.
39. Groves, H.M., Kinlough-Rathbone, R.L., Richardson, M., Jorgensen, L., Moore, S. and Mustard, J.F. Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest 1982, 46: 605-12.
40. Giesen, P.L., Fyfe, B.S., Fallon, J.T. et al. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost 2000, 83: 622-8.
41. Taubman, M.B. Tissue factor regulation in vascular smooth muscle: A summary of studies performed using in vivo and in vitro models. Am J Cardiol 1993, 72: 55C-60C.
42. Hatakeyama, K., Asada, Y., Maratsuka, K., Kataoka, H., Sato, Y. and Sumiyoshi, A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis 1998, 139: 265-71.
43. Marmur, J.D., Rossikhina, M., Guha, A. et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993, 91: 2253-9.
44. Sato, Y., Asada, Y., Marutsuka, K., Hatakeyama, K. and Sumiyoshi, A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996, 75: 389-92.
45. Sato, Y., Asada, Y., Marutsuka, K., Hatakeyama, K., Kamikubo, Y. and Sumiyoshi, A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997, 78: 1138-41.
46. Channon, K.M., Fulton, G.J., Davies, M.G. et al. Modulation of tissue factor protein expression in experimental venous bypass grafts. Arterioscler Thromb Vasc Biol 1997, 17: 1313-9.
47. Annex, B.H., Davies, M.G., Fulton, G.J. et al. Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts. J Surg Res 1998, 80: 164-70.
48. Huyah, T.T.T., Davies, M.G., Thompson, M.A., Ezekowitz, M.D., Hagen, P.O. and Annex, B.H. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 2001, 33: 400-7.
49. Valentin, S., Reutlingsperger, C.P., Nordfang O. and Lindhout, T. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: A comparison between tissue factor pathway inhibitor and inactive factor VIIA. Thromb Haemost 1995, 74: 1478-85.
50. Harker, L.A., Hanson, S.R., Wilcox, J.N. and Kelly, A.B. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996, 26(Suppl. 1): 76-82.
51. Arnljots, B., Ezban, M. and Hedner, U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997, 25: 341-6.
52. Golino, P., Ragni, M., Cirillo, P. et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998, 82: 39-46.
53. Jang, Y., Guzman, L.A., Lincoff, A.M. et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995, 92: 3041-50.
54. Sorensen, B.B., Persson, E. and Freskgard, P.O. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997, 272: 11863-8.
55. Golino, P., Cirillo, P., D'Andrea, D. et al. Long-term antithrombotic effects of human recombinant, active site-blocked factor VIIa in a chronic model of intravascular thrombosis. Circulation 1999, 98: Abstr. 1727.
56. Badimon, J.J., Lettino, M., Toschi, V. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999, 99: 1780-7.
57. Pawashe, A.B., Golino, P., Ambrosio, G. et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994, 74: 56-63.
58. Jang, I.K., Gold, H.K., Leinbach, R.C., Fallon, J.T., Collen, D. and Wilcox, J.N. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992, 12: 948-54.
59. Ragni, M., Cirillo, P., Pascucci, I. et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996, 93: 1913-8.
60. Golino, P., Ragni, M., Cirillo, P. et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996, 2: 35-40.
61. Kelley, R.F., Refino, C.J., O'Connell, M.P. et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997, 89: 3219-27.
62. Pierre, J. St., Yang, L.Y., Tamirisa, K. et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999, 19: 2263-8.
63. Kamikubo, Y., Nakahara, Y., Takemoto, S., Hamuro, T., Miyamoto, S. and Funatsu, A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997, 407: 116-20.
64. Rote, W.E., Oldeschulte, G.L., Dempsey, E.M. and Vlasuk, G.P. Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/Tissue Factor complex in animal models of arterial and venous thrombosis. Circulation 1996, 94(Suppl. I): Abstr. I-695.
65. Lee, A., Agnelli, G., Buller, H. et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001, 104: 74-8.
66. Haskel, E.J., Torr, S.R., Day, K.C. et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991, 84: 821-7.
67. Lindahl, A.K., Wildgoose, P., Lumsden, A.B. et al. Active site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons. Circulation 1993 88 (Suppl.): Abstr. 1-417.
68. Oltrona, L., Speidel, C.M., Recchia, D., Wickline, S.A., Eisenberg, P.R. and Abendschein, D.R. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997, 96: 646-52.
69. Zoldhelyi, P., McNatt, J., Shelat, H.S., Yamamoto, Y., Chen, Z.Q. and Willerson, J.T. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000, 101: 289-95.
70. Golino, P., Cirillo, P., Calabro, P. et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001, 38: 569-76.
71. Atsuchi, N., Nishida, T., Marutsuka, K. et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001, 103: 570-5.
72. Erhardtsen, E., Nilsson, P., Johannessen, M. and Thomsen, M.S. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001, 41: 880-5.
73. Lev, E.I., Marmur, J.D., Zdravkovic, M. et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: An ex vivo human study. Arterioscler Thromb Vasc Biol 2002, 22: 1036-41.
74. Lincoff, A.M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: A randomized, double-blinded, dose-escalation trial: Assessing safety and efficacy of FFR-rFVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. J Am Coll Cardiol. 2000, 36: Abstr. 312-3.